ArticleBlood advances2017
Epstein-Barr virus DNA in serum as an early prognostic marker in children and adolescents with Hodgkin lymphoma.
Article in Blood advances, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00025259 (A Phase III Groupwide Study of Dose-Intensive Response-Based Chemotherapy and Radiation Therapy for Children and Adolescents With Newly Diagnosed Intermediate Risk Hodgkin Disease), which is not on this map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase III Groupwide Study of Dose-Intensive Response-Based Chemotherapy and Radiation Therapy for Children and Adolescents With Newly Diagnosed Intermediate Risk Hodgkin Disease
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- The prognostic value of Epstein-Barr virus infection in Hodgkin lymphoma: A systematic review and meta-analysis.Frontiers in oncology · 2022Pooled it
- Targeted therapy with nanatinostat and valganciclovir in recurrent EBV-positive lymphoid malignancies: a phase 1b/2 study.Blood advances · 2023Trial
- Hodgkin lymphoma: the role of EBV plasma viral load testing in an HIV-endemic setting.Clinical and experimental medicine · 2024Article
- Worldwide Prevalence of Epstein-Barr Virus in Patients with Burkitt Lymphoma: A Systematic Review and Meta-Analysis.Diagnostics (Basel, Switzerland) · 2023Review
- Classical Hodgkin Lymphoma: From Past to Future-A Comprehensive Review of Pathophysiology and Therapeutic Advances.International journal of molecular sciences · 2023Review
- Diagnosis and monitoring of virus-associated cancer using cell-free DNA.Current opinion in virology · 2023Review
- Review
- Case Report: Chronic Active Epstein-Barr Virus Infection With Subcutaneous Nodules and Systemic Damage.Frontiers in medicine · 2022Article
- Advances in Lymphoma Molecular Diagnostics.Diagnostics (Basel, Switzerland) · 2021Review
- Review
- CpG methylation in cell-free Epstein-Barr virus DNA in patients with EBV-Hodgkin lymphoma.Blood advances · 2020Article
- High pretreatment plasma Epstein-Barr virus (EBV) DNA level is a poor prognostic marker in HIV-associated, EBV-negative diffuse large B-cell lymphoma in Malawi.Cancer medicine · 2020Observational
- Epstein-Barr virus infection is associated with clinical characteristics and poor prognosis of multiple myeloma.Bioscience reports · 2019Article
- Methylation analysis of plasma DNA informs etiologies of Epstein-Barr virus-associated diseases.Nature communications · 2019Article
- Sensitive detection of DNA from Chlamydia trachomatis by using flap endonuclease-assisted amplification and graphene oxide-based fluorescence signaling.Mikrochimica acta · 2019Article
- Plasma Epstein-Barr virus DNA as an archetypal circulating tumour DNA marker.The Journal of pathology · 2019Review
- Advances in the Study of Chronic Active Epstein-Barr Virus Infection: Clinical Features Under the 2016 WHO Classification and Mechanisms of Development.Frontiers in pediatrics · 2019Review
- Does Size Matter? Comparison of Extraction Yields for Different-Sized DNA Fragments by Seven Different Routine and Four New Circulating Cell-Free Extraction Methods.Journal of clinical microbiology · 2018Article
- Ultrasensitive DNA detection based on target-triggered rolling circle amplification and fluorescent poly(thymine)-templated copper nanoparticles.RSC advances · 2018Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 9 institutions in 1 country.
Funding
Abstract
Assay of cell-free DNA in blood offers an approach to assessment of tumor DNA. We sought to determine whether Epstein-Barr virus (EBV) DNA in cell-free blood is also a good surrogate for the presence of tumor DNA in children with Hodgkin lymphoma, as it is in adults, and whether it correlates with pediatric outcomes. Pediatric patients enrolled in a Children's Oncology Group trial (AHOD0031) were studied at baseline and at 8 days after the initiation of treatment. At baseline, EBV DNA in cell-free blood correlated with the presence of EBV in tumor, and EBV DNA 8 days after the initiation of therapy predicted inferior event-free survival. EBV DNA in cell-free blood warrants further investigation as a marker of inadequate tumor response in Hodgkin lymphoma. This trial was registered at www.clinicaltrials.gov as #NCT00025259.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.